Novartis asks court for access to rival’s documents over trade secrets claims

Swiss multinational says competitor has been “uncooperative” in investigation into whether former Novartis employee took trade secrets |Novartis files complaint for discovery, asking for permission to issue subpoena.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Novartis ends eight-year cancer drug dispute for $182m

7 December 2023 Case dismissed with settlement between Novartis and Daiichi Sankyo unit | Melanoma therapy at centre of feud after Novartis faced infringement claims over Tafinlar.

Generics

Novartis vows to challenge heart drug patent loss

11 July 2023 Decision affects a patent listed in the Orange Book | Generic drug makers have so far failed to secure approval for biosimilar versions of the blockbuster drug.

Big Pharma

Novartis ‘abused’ discovery process for Zolgensma patent

23 May 2023 Two subsidiaries of the French pharma giant allege ‘wilful’ patent infringement by the Swiss-American pharma firm | Novartis ‘hid’ information in a previous lawsuit relating to spinal muscular atrophy drug used to treat young children.

More on this story

Big Pharma

Novartis ends eight-year cancer drug dispute for $182m

7 December 2023 Case dismissed with settlement between Novartis and Daiichi Sankyo unit | Melanoma therapy at centre of feud after Novartis faced infringement claims over Tafinlar.

Generics

Novartis vows to challenge heart drug patent loss

11 July 2023 Decision affects a patent listed in the Orange Book | Generic drug makers have so far failed to secure approval for biosimilar versions of the blockbuster drug.

Big Pharma

Novartis ‘abused’ discovery process for Zolgensma patent

More on this story

Big Pharma

Novartis ends eight-year cancer drug dispute for $182m

7 December 2023 Case dismissed with settlement between Novartis and Daiichi Sankyo unit | Melanoma therapy at centre of feud after Novartis faced infringement claims over Tafinlar.

Generics

Novartis vows to challenge heart drug patent loss

11 July 2023 Decision affects a patent listed in the Orange Book | Generic drug makers have so far failed to secure approval for biosimilar versions of the blockbuster drug.

Big Pharma

Novartis ‘abused’ discovery process for Zolgensma patent